Heart Failure Clinical Trials in Bradenton, Florida

4 studies are recruiting for heart failure in Bradenton, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Bradenton, FL Investigative Site 10125, Bradenton, Florida
    Locations
    356 in total
    Run by
    Colorado Prevention Center
  2. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

    Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Bradenton, FL Investigative Site CON-10125, Bradenton, Florida
    Locations
    140 in total
    Run by
    Colorado Prevention Center
  3. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage
    Not phased
    Ages
    Any age
    Site
    Research site, Bradenton, Florida
    Locations
    333 in total
    Run by
    Medtronic
  4. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Bradenton, FL Investigative Site FIN-10125, Bradenton, Florida
    Locations
    176 in total
    Run by
    Colorado Prevention Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.